New pill could tame deadly heart flutters during exercise

NCT ID NCT07263139

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new oral drug called AGP100 in people with a rare inherited heart condition (CPVT) that can cause dangerously fast heartbeats during stress or exercise. Ten adults aged 18-75 will take three different doses of AGP100 over six weeks while continuing their usual heart medications. Researchers will check if the drug is safe and helps maintain a normal heart rhythm during exercise.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AGP100 (oral capsule)
What this could lead to
If successful, AGP100 could offer a new treatment option to better control dangerous heart rhythms in people with CPVT, potentially improving their ability to exercise safely.
What could go wrong
This is a small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve heart rhythm control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

catecholaminergic polymorphic ventricular tachycardia Polymorphic Catecholaminergic Ventricular Tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Cardiology, Oslo University Hospital

    RECRUITING

    Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.